Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 12Recruiting 3Withdrawn 2Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 80Sarcoma 23Dermatologic 19Thoracic 7Lymphoid 5Endocrine 3Breast 3Tumor-Agnostic 2Other solid neoplasm 2Genitourinary 2Gastrointestinal 2Other hematologic neoplasm 1NET 1Head & Neck 1Gynecologic 1Classical hematology 1

Conditions

Solid Tumors 1Retinoblastoma 1

Interventions

pembrolizumab 26Cisplatin 15Pemetrexed 14Paclitaxel 14Carboplatin 14Nivolumab 9Cyclophosphamide 9Docetaxel 8Injections 7atezolizumab 6Melphalan 6olaparib 5Gemcitabine 5Filgrastim 5tislelizumab 4durvalumab 4aldesleukin 4Leucovorin 4Irinotecan 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Bevacizumab 4tocilizumab 3spartalizumab 3liposomal doxorubicin 3ixabepilone 3fludarabine 3epacadostat 3defactinib 3adavosertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Temozolomide × Other solid neoplasm × Clear all
NCT01127178 2024-10-10

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

Eisai Inc.

Phase 1 Terminated
12 enrolled 13 charts
Other solid neoplasm

Solid Tumors

NCT01857752 2017-01-30

Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala

Stanford University

Phase 2 Terminated
3 enrolled
Other solid neoplasm

Retinoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡